在因m.3243A>G突变而导致线粒体疾病的患者中使用sonlicromanol的2b期计划
Jan Smeitink1, Just van Es2, Brigitte Bosman1
1Khondrion B.V., 6534 AT Nijmegen, The Netherlands.
Brain : a journal of neurology
|November 6, 2024
概括
索尼克罗曼醇显示出治疗线粒体疾病的前景,改善了m.3243A>G突变患者的疲劳和疼痛等症状. 长期治疗显示出良好的安全性和有效性,特别是在受影响较大的个体中.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 遗传学 遗传学 是一个
背景情况:
- 线粒体疾病是罕见的,使人衰弱的疾病,缺乏经批准的治疗方法,需要紧急的治疗开发.
- 索尼克罗曼醇是一种减少和氧化应激的新型调节剂,向关键的代谢和炎症途径,与线粒体疾病有关.
- m.3243A>G突变是主要线粒体疾病的常见原因,影响多个器官系统.
研究的目的:
- 为了评估sonlicromanol的安全性,耐受性和有效性,在成年人中,由于m.3243A>G突变导致的初级线粒体疾病.
- 通过随机对照试验 (RCT) 确定sonlicromanol的最佳剂量,并在开放式扩展 (EXT) 研究中评估长期结果.
- 研究sonlicromanol对认知功能,情绪,疲劳,疼痛和身体功能的影响.
主要方法:
- 一个2b期计划,包括28天的RCT (剂量选择),随后是52周的开放扩展 (EXT) 研究.
- 在RCT中,患者每天两次服用sonlicromanol (100 mg或50 mg) 或安慰剂,在EXT中,所有参与者每天两次服用100 mg.
- 通过认知测试 (Cogstate IDN,TAP),患者报告的问卷 (BDI,CFQ,HADS,SF-36,Neuro-QoL,McGill Pain) 和功能测试 (五次坐到站,m-BESTest,EQ-5D-5L) 来评估结果.
主要成果:
- 索尼克罗曼醇耐受性良好,并在一年内显示出良好的安全性.
- 虽然主要的RCT终点 (Cogstate IDN) 没有达到统计学意义,但根据基线严重程度的分析显示了治疗效应与安慰剂相比.
- 在EXT研究中,在多个患者报告和临床医生评估的结果中观察到显著的改善,包括情绪 (BDI,HADS),疲劳 (Neuro-QoL),疼痛 (RAND-SF-36,McGill) 和身体功能 (m-BESTest,5次坐到站,SF-12 PCS).
结论:
- 索尼克罗曼醇耐受性良好,在患有m.3243A>G线粒体疾病的患者中,它在长达一年的时间内显示出有利的益处/风险比率.
- 在各种临床相关领域观察到有效性,特别是在基线损伤较大的患者中.
- 用sonlicromanol长期治疗导致更明显的改善,表明作为线粒体疾病症状管理的治疗选择的潜力.
相关概念视频
01:17Phase II Reactions: Methylation Reactions
160
Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
160
01:19Phase II Reactions: Miscellaneous Conjugation Reactions
48
Phase II biotransformations are detoxification mechanisms that conjugate xenobiotics with endogenous substances, neutralizing their toxicity.
A key example involves the conjugation of cyanide ions, which impair cellular respiration and alter hemoglobin into non-oxygen-carrying cyanmethemoglobin. To neutralize this threat, a sulfur atom from thiosulphate is transferred to the cyanide ion, catalyzed by the enzyme rhodanese, resulting in an inactive compound called thiocyanate. The production of...
A key example involves the conjugation of cyanide ions, which impair cellular respiration and alter hemoglobin into non-oxygen-carrying cyanmethemoglobin. To neutralize this threat, a sulfur atom from thiosulphate is transferred to the cyanide ion, catalyzed by the enzyme rhodanese, resulting in an inactive compound called thiocyanate. The production of...
48
01:19Phase II Reactions: Sulfation and Conjugation with α-Amino Acids
190
Sulfation and α-amino acid conjugation are two critical biotransformation reactions in drug metabolism. Sulfation, a phase II biotransformation reaction, involves adding a polar sulfate group to a drug, enhancing its water solubility and promoting excretion. This process can either co-occur with or occur independently of glucuronidation. Nonmicrosomal sulfotransferase enzymes catalyze the process. The reaction involves 3'-phosphoadenosine-5'-phosphosulfate or PAPS coenzyme...
190